Гипергомоцистеинемия -дополнительный фактор риска тромбозов при системной красной волчанке и антифосфолипидном синдроме
https://doi.org/10.14412/1995-4484-2003-1331
Аннотация
Список литературы
1. <div><p>Алекберова З.С., Попкова Т. В., Насонов Е.Л. с соавт. Липид-белковые системы транспорта холестерина у больных системной красной волчанкой в зависимости от антифосфолипндного синдрома. Тер.архив, 1999, 5, 34-38.</p><p>Баркаган З.С., Момот А.П. Основы диагностики нарушения гемостаза. М., Ныодиамед-АО, 1999, 215.</p><p>Насонова В.А. Системная красная волчанка. М., Медицина, 1972.</p><p>Насонов ЕЛ., Карпов Ю.А., Алекберова З.С. Антифо- сфолипидный синдром: кардиологические аспек- ты.Тер.архив, 1993,11, 5-13.</p><p>Abu-Shakra М., Urowitz М.В., Gladinan D.D. et al. Mortality studies in SLE. Results from a single center. I. Causes of death. J Rheumatol., 1995, 22,1259-1264.</p><p>Alpert M.A. Homocyst(e)ine, atherosclerosis and thrombosis. South Med. J. 1999, 92 (9). 858-865.</p><p>Asherson R.A., Rhamaihta M.A., Ordi-Ros J. et al. The "primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore), 1989, 68, 366374.</p><p>Bruce IN, Burns RJ. High prelevance of myocardial perfusion abnormalities in women with SLE. Arthr. Rheum, 1997, 40 (suppl.9), 219.</p><p>Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb. Haemost., 1999, 81, 65-76.</p><p>DAngello A., Mazzola G., Grippa L. Hyperhomocysteine- mia and venous thromboembolic disease. Haematologica,, 1997, 82, 211-219.</p><p>Exner Т., Sahman N. Trudinger B. Separation of anticar- diolipin antibodies from lupus anticoagulant on phospho- lipidcoated polysterine column. Biochem. Biophys. Res.Commun., 1988, 155, 1001-1007.</p><p>Falconi C.R., Cattaneo M. Prevalence of moderate hyper- homocysteinemia in patients with early- onset venouse and arterial occlusive disease. Ann. Intern. Med., 1995, 123, 747.</p><p>Fijnheer R. Roest М., Haas FJ. et al. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study J. Rheumatol., 1998, 25(9), 1737-1742.</p><p>Harker L.A., Ross R., Slichter S.J., Scott C.R. Homocysteine-induced arteriosclerosis. The role of endothelial cell injure and platelet response in its genesis. J. Clin.Invest., 1976, 58, 731-741.</p><p>Hughes G.R.V., Harris E.N., Charavi А.Е. The anlicardi- olipin syndrome. J.Reumatol., 1986, 13, 486-489.</p><p>Jensen R. The new markers of cardiovascular risk. Clin. Haemostasis Rev., 2000, 14, 1-4.</p><p>Petri М., RoubenotT R., Dallal G.E. et al. Plasma homocysteine as a risk factor for atherothroinbotic events in systemic lupus erythematosus. Lancet, 1996. 26, 348(9035), 1120-1124.</p><p>Saez G., Thornalley P.J., Hill H.A. et al. The production of free redicals during the autoxidation of cysteine and their eflecl on isolated rat hepatocytes. Biochim. Biophys., 1982. 719, 24-31,</p><p>Seriolo B., Fasciolo D., Sulli A. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin. Exp.Rheumatol., 2001, 19(5), 561-564.</p><p>SeLhub J., Jacques P.F., Wilson P.W. et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA., 1993. 270, 2693-2698.</p><p>Starkebaum G., Harlan M. Endothelial cell injure due lo copper-catalysed hydrogen peroxide generation from homocysteine. J.Clin.Invest., 1986, 77, 1370-1376.</p><p>Svenungsson E., Jensen-Urstad K., Heimburger M. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. J.Circulation, 2001, 16,104(16), 1887-1893,</p><p>Tan E.M., Cohen A.S., Fries J.F. et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthr. Rheum., 1982. 136, 347-354.</p><p>Tsai J-С., Perrella M.A., Yoshizumi M. et al. Promolion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc.Natl. Acad. Sci. (USA), 1994, 91, 6369-6373.</p><p>Upchurch G.R., Welch G.N. Homocysteine attenuates endothelial glutatione peroxidase and thereby potentiates peroxide-mediated cell injure. Circulation, 1995, 92, 1228.</p><p>Vianna J.K., Khamasha M.A., Ordi-Ros J., et al. Comparision of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am. J. Med., 1994, 96, 3-9.</p><p>Zmuda J.M., Bausserman L.L., Maceroni D. The effect of supraphysiologic doses of testosteroni on fasting total homocysteine levels in normal men. Atherosclerosis, 1997. 130. 199-202.</p><p>Welch G.N, Upchurch G., Loscalzo J, Hyperhomo- cyst(e)inemia and atherothrombosis. Ann. N. Y. Acad. Sci,1997, 15, 811.48-58.</p></div><br />
Рецензия
Для цитирования:
Shirokova I.E., Reshelnyak T.M. Гипергомоцистеинемия -дополнительный фактор риска тромбозов при системной красной волчанке и антифосфолипидном синдроме. Научно-практическая ревматология. 2003;41(4):39-43. https://doi.org/10.14412/1995-4484-2003-1331
For citation:
Shirokova I.E., Reshelnyak T.M. Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Rheumatology Science and Practice. 2003;41(4):39-43. (In Russ.) https://doi.org/10.14412/1995-4484-2003-1331